Terms: = Breast cancer AND MAP2K2, MEK2, 5605, ENSG00000126934, P36507, MKK2, MAPKK2, PRKMK2 AND Treatment
8 results:
1. Super-enhancer-controlled positive feedback loop BRD4/ERα-RET-ERα promotes ERα-positive breast cancer.
Zheng ZZ; Xia L; Hu GS; Liu JY; Hu YH; Chen YJ; Peng JY; Zhang WJ; Liu W
Nucleic Acids Res; 2022 Oct; 50(18):10230-10248. PubMed ID: 36124682
[TBL] [Abstract] [Full Text] [Related]
2. O-GlcNAcylation of mek2 promotes the proliferation and migration of breast cancer cells.
Xu Y; Sheng X; Zhao T; Zhang L; Ruan Y; Lu H
Glycobiology; 2021 Jun; 31(5):571-581. PubMed ID: 33226073
[TBL] [Abstract] [Full Text] [Related]
3. IGF-1R inhibition induces MEK phosphorylation to promote survival in colon carcinomas.
Wang Q; Zhang Y; Zhu J; Zheng H; Chen S; Chen L; Yang HS
Signal Transduct Target Ther; 2020 Aug; 5(1):153. PubMed ID: 32843616
[TBL] [Abstract] [Full Text] [Related]
4. Clinically advanced and metastatic pure mucinous carcinoma of the breast: a comprehensive genomic profiling study.
Ross JS; Gay LM; Nozad S; Wang K; Ali SM; Boguniewicz A; Khaira D; Johnson A; Elvin JA; Vergilio JA; Suh J; Miller VA; Stephens PJ
Breast Cancer Res Treat; 2016 Jan; 155(2):405-13. PubMed ID: 26762307
[TBL] [Abstract] [Full Text] [Related]
5. Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer.
Duncan JS; Whittle MC; Nakamura K; Abell AN; Midland AA; Zawistowski JS; Johnson NL; Granger DA; Jordan NV; Darr DB; Usary J; Kuan PF; Smalley DM; Major B; He X; Hoadley KA; Zhou B; Sharpless NE; Perou CM; Kim WY; Gomez SM; Chen X; Jin J; Frye SV; Earp HS; Graves LM; Johnson GL
Cell; 2012 Apr; 149(2):307-21. PubMed ID: 22500798
[TBL] [Abstract] [Full Text] [Related]
6. An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: Gefitinib (Iressa) -induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands (Review).
Ferrer-Soler L; Vazquez-Martin A; Brunet J; Menendez JA; De Llorens R; Colomer R
Int J Mol Med; 2007 Jul; 20(1):3-10. PubMed ID: 17549382
[TBL] [Abstract] [Full Text] [Related]
7. Patient time costs associated with cancer care.
Yabroff KR; Davis WW; Lamont EB; Fahey A; Topor M; Brown ML; Warren JL
J Natl Cancer Inst; 2007 Jan; 99(1):14-23. PubMed ID: 17202109
[TBL] [Abstract] [Full Text] [Related]
8. CI-1040 (PD184352), a targeted signal transduction inhibitor of MEK (MAPKK).
Allen LF; Sebolt-Leopold J; Meyer MB
Semin Oncol; 2003 Oct; 30(5 Suppl 16):105-16. PubMed ID: 14613031
[TBL] [Abstract] [Full Text] [Related]
